ITeos Therapeutics
Cambridge · Founded 2011
About ITeos Therapeutics
ITeos Therapeutics is a private biotechnology company targeting the metabolism of the tumor microenvironment to develop small molecule immunomodulators for cancer treatments. iTeos is building its activities upon the unparalleled expertise of the Ludwig Cancer Research (LICR) – a world-class Research Institute in the fields of tumor immunology, therapeutic cancer vaccines, cancer biology, and translational medicine in cancer. iTeos endeavors to develop small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints (e.g. anti-CTLA4, anti-PD1, and anti-PDL1 antibodies).
Company Facts
- Founded: 2011
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 101 – 250
- Estimated revenue: $1K – $10K
- Total funding: $369.7M
- Funding stage: M&A
- Last round: Post-IPO Equity (May 2024)
- Ticker: nasdaq:ITOS
- Website: http://iteostherapeutics.com/
- Phone: 3271919934
Industries & Categories
Biotechnology, Health Care, Medical
Social Profiles
Canonical: https://fsome.com/organization/iteos-therapeutics-90023 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.